6-[4-(3-trifluoromethylpyridin-2-yl)piperazin-1-yl]pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide | 1026746-07-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-[4-(3-trifluoromethylpyridin-2-yl)piperazin-1-yl]pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide
• 英文别名: N-(2-cyclopropylethyl)-6-[4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]pyridazine-3-carboxamide
• CAS: 1026746-07-5
• 化学式: C₂₀H₂₃F₃N₆O
• 分子量: 420.437
• InChiKey: JSQLFBLIHMASQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  1-[3-(三氟甲基)吡啶-2-基]哌嗪 、 1-(4-氟苯基)哌嗪 、 6-氯-N-(2-环丙基乙基)吡嗪-3-羧酰胺 以the title compound was obtained as a white powder in 43% yield (0.061 g)的产率得到6-[4-(3-trifluoromethylpyridin-2-yl)piperazin-1-yl]pyridazine-3-carboxylic acid (2-cyclopropylethyl)amide
  参考文献：
  名称：

  HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS

  摘要：

  本发明涉及用于治疗哺乳动物，尤其是人体中SCD介导的疾病或病况的方法，其中所述方法包括向需要治疗的哺乳动物中给予化合物(I)的组合物，其中x、y、G、J、K、L、M、W、R2、R3、R5、R5a、R6、R6a、R7、R7a、R8和R8a在此定义。还公开了含有化合物(I)的制药组合物。

  公开号：

  US20090306090A1

文献信息

• Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors
  申请人：Kamboj Rajender

  公开号：US20080125434A1

  公开（公告）日：2008-05-29

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R 2 , R 3 , R 5 , R 5a , R 6 , R 6a , R 7 , R 7a , R 8 and R 8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本发明揭示了一种治疗哺乳动物（优选为人类）SCD介导的疾病或病症的方法，其中该方法包括向需要治疗的哺乳动物施用化合物I的方法：其中x、y、G、J、K、L、M、W、R2、R3、R5、R5a、R6、R6a、R7、R7a、R8和R8a在此定义。本发明还揭示了包含化合物I的药物组合物。
• Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US07592343B2

  公开（公告）日：2009-09-22

  Compounds of formula (Ia): where x, y, G, L, M, W, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, are disclosed, as well as pharmaceutical compositions comprising the compounds. These compounds and pharmaceutical compositions are useful in treating SCD-mediated diseases or conditions.

  公式（Ia）的复合物：其中x，y，G，L，M，W，R2，R3，R5，R5a，R6，R6a，R7，R7a，R8和R8a的定义如本文所述，以及包含这些化合物的制药组合物已经披露。这些化合物和制药组合物在治疗SCD介导的疾病或病况方面是有用的。
• Substituted pyridazines as stearoyl-CoA desaturase inhibitors
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US08026360B2

  公开（公告）日：2011-09-27

  Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

  本文公开了治疗哺乳动物，尤其是人类SCD介导的疾病或病症的方法，其中该方法包括向需要治疗的哺乳动物施用以下化合物（I）：其中x、y、G、J、K、L、M、W、R2、R3、R5、R5a、R6、R6a、R7、R7a、R8和R8a在此定义。本文还公开了包含化合物（I）的制药组合物。
• Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
  申请人：Xenon Pharmaceuticals Inc.

  公开号：EP1804799B1

  公开（公告）日：2013-08-21
• US7592343B2
  申请人：——

  公开号：US7592343B2

  公开（公告）日：2009-09-22